Press Release|Articles|May 1, 2025
Camber Pharmaceuticals Announces Addition of Phenylephrine Hydrochloride Injection, USP
Listen
0:00 / 0:00
Key Takeaways
- Camber Pharmaceuticals introduces Phenylephrine Hydrochloride Injection, USP for treating hypotension due to vasodilation during anesthesia.
- Available in 10 mg/mL single-dose vials, 50 mg/5 mL vials, and 100 mg/10 mL vials.
Advertisement
Camber Pharmaceuticals is excited to announce the addition of Phenylephrine Hydrochloride Injection, USP to their portfolio.
Phenylephrine Hydrochloride Injection, USP is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.
Phenylephrine Hydrochloride Injection, USP are available in:
- 10 mg/mL | 25 x 1 mL Single-Dose Vials
- 50 mg/5 mL (10 mg/mL) | 10 x 5 mL Vials
- 100 mg/10 mL (10 mg/mL) | 10 mL Vial
To find out more information on Phenylephrine Injection, USP , please visit:
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Cyclosporiasis on the Rise in the United States, Exceeding 450 Cases
2
Kidney Disease Rates Hold Steady for a Decade as Diabetes-Driven Cases Climb
3
Same-Day COVID-19 and Flu Vaccination Does Not Raise Adverse Event Risk, Large VA Study Finds
4
Reducing Recurrence in C Difficile Infection
5